Ketamine, an anesthetic agent primarily used in veterinary medicine and pediatrics, continues to gain in popularity in the drug abuse scene or "Rave Wave" of all-night dance clubs. The Division of Forensic Toxicology Laboratory (Office of the Armed Forces Medical Examiner) at the Armed Forces Institute of Pathology, as the primary analytical laboratory for criminal investigative agencies in the Department of Defense (DOD), has seen requests for ketamine analysis rise from I in 1997 to 116 in 2000. This increasing abuse has led the DOD Urine Drug Testing Laboratories to consider adding ketamine screening to their random urinalysis program. However, before ketamine testing can be implemented as standard policy, concentrations of ketamine and metabolites in urine need to be evaluated after actual drug use. There is very little information regarding the pharmacokinetics of ketamine, especially concentrations of the drug or its two major metabolites, norketamine and dehydronorketamine, that can be expected in urine. In fact, dehydronorketamine has been believed to be an analytical artifact caused by the high temperatures of gas chromatography. In this paper, we attempt to resolve this issue with the development of a liquid chromatography-mass spectrometry (LC-MS) method. The urine concentrations of ketamine, norketamine and dehydronorketamine (presumptive) detected in 33 "positive" cases received in our laboratory since 1998 are reported. Quantitations were accomplished with LC-MS. Ketamine concentrations ranged from 6 to 7744 ng/mL. Norketamine concentrations ranged from 7 to 7986 ng/mL and dehydronorketamine (presumptive) concentrations ranged from 37 to 23,239 ng/mL.
Introduction
Ketamine hydrochloride is marketed as an anesthetic for human and veterinary use. Also known as "K," "Special-K,"
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and "Kit-Kat", ketamine produces effects similar to those produced by phencyclidine (PCP) with the visual effects of LSD. Ketamine also maintains self-administration behavior similarly to central nervous system (CNS) depressant drugs (1) . As a result, the potential for ketamine abuse is not surprising. Ketamine first became popular on the European party scene in the early 1990s but quickly spread to the United States, where use seems to be regionalized to Florida, New York, and the West Coast. It is sometimes mixed with other drugs such as methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy), cocaine, heroin, and various benzodiazepines and sold as "Trail Mix". Evidence of ketamine's escalating abuse includes increased arrests for "driving under the influence" of ketamine and burglaries of ketamine from veterinary clinics. Additionally, between 1990 and 1995, confiscation reports filed with the Drug Enforcement Agency (DEA) from police laboratories jumped from 2 to 47 (2) . These concerns led the DEA to place ketamine into Schedule III of the Controlled Substances Act, effective August 12, 1999.
Requests from Department of Defense (DOD) criminal investigative agencies to this laboratory for ketamine analysis in suspected drug abusers have increased ]00-fold between 1997 and 2000. Because this sharp increase in requests reflects only active investigations of illegal ketamine use, the potential for undetected and widespread use is high. Investigators believe that ketamine abuse is increasing because it is not currently tested for by the DOD Urine Drug Testing Laboratories in the military's random urinalysis program. These laboratories are considering adding this drug to their standard screening procedures. However, before this testing can become standard policy, much more information is required on expected urine ketamine and metabolite concentrations in abuse situations.
The primary purpose of this study was to determine urinary concentrations of ketamine, norketamine (NK) and dehydronorketamine (DNK, presumptive) in 33 cases of ketamine abuse received in this laboratory between 1998 and 2000. When available, history is provided regarding the time elapsed between use and specimen collection.
The second purpose was to add to the limited body of knowl-edge on the urinary excretion of ketamine in humans. Ketamine is believed to be metabolized to at least two major metabolites: N-demethylation of the parent drug to NK, followed by dehydrogenation to DNK (3). It has been suggested that DNK is an artifact of the analytical process rather than a metabolite (4) . Despite the fact that we were unable to obtain a reference standard for DNK, the development of a liquid chromatography-mass spectrometry (LC-MS) method for the analysis of ketamine and its metabolites should provide some circumstantial evidence to resolve this issue as to whether it is a metabolite or analytical artifact. These data will be useful in determining the best target analyte for ketamine abuse as well as potential quantitative cutoffs.
Experimental Materials
Ketamine hydrochloride standard was obtained from U.S.P.C., Inc. (Rockville, MD). NK and ketamine-d4 were purchased from Cerilliant (Austin, TX). SK&F #525-A ("Proadifen') was purchased from Smith, Kline and French Laboratories (Philadelphia, PA). CLEAN SCREEN | solid-phase extraction columns (ZSDAU020) were purchased from United Chemical Technologies, Inc. (Bristol, PA). All other reagents were J.T. Baker Reagent grade and solvents were Fisher Optima grade. Calibrators and controls were made in AFIP Negative Urine purchased from Bio-Rad ECS Division (Anaheim, CA).
Extraction (LC-MS)
Working standards (0.1 mg/mL) were prepared from 1.0 mg/mL ketamine and norketamine standards (in methanol). Samples, calibrators (4, 25, 100, 500, and 1000 ng/mL), and controls were extracted from 2 mL urine. Twenty microliters of ketamine-d4 (prepared as a 0.01 mg/L internal standard in methanol) was added to all tubes. Two milliliters of potassium phosphate buffer (pH 8.7) and 3 mL of toluene/butanol (9:1) were added to each tube; the tubes were capped and rotated for 10 min.
The tubes were then centrifuged at 3000 rpm for 5 min to achieve phase separation. The top (organic) layer was transferred to clean 10-mL conical test tubes and dried under a gentle stream of nitrogen in a water bath at 40-60~ The residue was reconstituted in 50 mL of mobile phase (20mM ammonium formate pH 4.3/acetonitrile, 3:1) and transferred to autosampler vials containing reduced volume inserts. Ten microliters was injected into the LC-MS for analysis.
Instrumentation
LC-MS analysis was performed using an Agilent Technologies (Agilent, Palo Alto, CA) ]100 series LC consisting of a binary pump, vacuum degasser, autosampler, and thermostatted column compartment. Analytical separation was achieved with an Agilent Eclipse-XDB C8 column (50 mmx 4.6-ram i.d., 3.5-mm particle size) which was maintained at 35~ The mobile phase consisted of 20raM ammonium formate pH 4.3 (A) and acetonitrile (B) at an isocratic elution of 75% A and 25% B. A flow rate of 0.800 mL/min was maintained throughout the 3-min separation. Using these conditions, the retention times were 1.21,1.23, 1.26, and 1.88 rain for ketamine-d4, ketamine, NK, and DNK, respectively.
An Agilent 1100 mass selective detector was used for mass spectral analysis. Electrospray ionization was used with nitrogen performing both the nebulization and evaporation of the mobile phase. The drying gas was maintained at a flow rate of 13 L/rain at 350~ and the nebulizer pressure was 40 psi. The instrument calibration was checked daily by infusion of the proprietary electrospray calibration compound purchased from Agilent. The capillary voltage was set to 4 kV and the fragmentor voltage was 55 V. Mass spectra were collected over the mass-to-charge ratio range 210-250 with a 0.08-rain peak width resulting in a 750 ms cycle time per scan. (m/z 242), NK (m/z 224), and DNK (m/z 222). Quantitation was based on internal standard corrected peak areas for all compounds with DNK calculations estimated by comparison with the 100-ng/mL NK calibrator.
Tandem MS experiments were conducted using an Agilent 1100 MSD ion trap. LC separation and MS interfacing were identical to that used for the LC-MS analysis. Collisioninduced dissociation (CID) was used with a helium pressure of 6.0 x 104 mbar. The precursor m/z 222 was isolated with a 4-amu window before dissociation with a resonant excitation voltage of 0.8 V applied for 40 ms. A mass cutoff ofm/z 60 was maintained to trap product ions following CID. Ion charge control was maintained with a target setting of 50,000 and the product masses were acquired from m/z 100 to m/z 230 with spectral averaging set to 3. The product ions m/z 205 and 177 were monitored for the identification of DNK.
Confirmation by gas chromatography-mass spectrometry (GC-MS)
Ketamine was confirmed in all samples by full-scan GC-MS following solid-phase extraction of a second aliquot. Samples, calibrators (10, 100, and 200 ng/mL), and controls were extracted from 5 mL urine. Following centrifugation of the urine samples at 3000 rpm for 10 rain, 5 mL of supernatant was removed to clean 16 x 125-mm test tubes. Fifty microliters of 0.1 mg/mL SK&F #525-A (internal standard) was added to all tubes.
Urine samples were extracted using a solid-phase extraction procedure modified from United Chemical Technologies, Inc. Methods Manual for alkaline drugs. The C-8 extraction columns were conditioned by sequential rinsing with 3.0 mL methanol, 3.0 mL deionized water, and 2.0 mL 0.1M phosphate buffer (pH 6.0). Aspiration was at ~ 3 mm Hg to prevent sorbent drying. Samples were then placed at the head of the column and aspirated at 1-2 mL/min. The columns were washed with 3 mL deionized water, 2 mL 20% acetonitrile in water, and 1 mL 0.1M acetic acid. Vacuum was applied at > 10 mm Hg for 3 rain. The columns were rinsed with 2 mL hexane, 3 mL hexane/ethyl acetate (1:1), and 3 mL methanol. Columns were dried again under reduced vacuum for 3 rain. Ketamine and internal standard were eluted with 2 mL methylene chloride/isopropanol/ ammonium hydroxide (78:20:2). The eluates were collected in clean tubes and evaporated to dryness under a gentle stream of nitrogen. The residue was reconstituted in 501JL of methanol and transferred to autosampler vials containing reduced volume inserts.
Two microliters was injected (splitless) onto an Agilent Technologies 6890 GC equipped with a DB-5 (Agilent, formerly J&W, Palo Alto, CA) 25-m x 0.32-ram x 0.17-mm i.d. capillary column. The GC oven was held at 70~ for I min then ramped to 240~ at 20~ and held at this temperature for an additional 2 rain. The transfer line was heated at 290~ and the injector was held at 275~ Helium was used as the carrier gas at a constant pressure of 5 psi. An Agilent Technologies 5973 MSD was used for detection in the full scan mode with an acquisition mass range of m/z 40-500. The identity of ketamine was confirmed by comparison of the retention time and mass spectrum of case samples to those of positive controls. Norke- Figure I and illustrates the DNK-presumptive peak.
Results
The linear range (4-1000 ng/mL) of the LC-MS method for K and NK routinely produced correlation coefficients greater than 0.995. Samples that were found to contain ketamine and metabolites in excess of the upper limits of linearity were reanalyzed following sample dilution with negative urine. Limits of detection of 3 ng/mL for both analytes were measured with signal-to-noise ratios greater than 5. The LC-MS chromatogram for case 18 is shown in Figure 2 and demonstrates the chromatography near the LOQ.
Ketamine, NK, and DNK (presumptive) concentrations are listed in Table I along with any available histories. Further confirmation of DNK was accomplished by reanalysis using an LC-MS-MS method to detect fragment ions m/z 205 and m/z 177 as described in a previous publication which used an authentic standard of DNK (5). Kochhar published both EI and methane CI-MS spectra. The MS-MS spectra are generated after electrospray ionization, which results in a spectrum similar to that of positive CI-MS (Figure 3) . The 205 and 177 fragments are referenced as metabolite II by Kochhar (5). The 205 base peak corresponds to the loss of ammonia from the protonated dehydronorketamine. As noted by this author, metabolite II was the "principle excretion product in urine".
Discussion
Ketamine was originally investigated in the 1960s as an alternative intravenous (IV) anesthetic agent when widespread use of phencyclidine (PCP, Sernyl | and its congener, cyclohexamine, were precluded from Food and Drug Administration (FDA) clearance because of the undesirable production of longlasting, postanesthetic psychotomimetic activity. This class of injectable anesthetics are often referred to as "dissociative" anesthetics, so-called because they induce anesthesia by disrupting the flow of information from the conscious to the unconscious parts of the brain, rather than the generalized depression of all brain centers typical of other anesthetics, such as inhalants (6) . Ketamine was found to produce adequate surgical anesthesia with a rapid recovery and was approved for use in 1970. However, its clinical usefulness has since been limited because of its cardiovascular stimulating properties and high incidence of disturbing emergence reactions.
The psychic sensations reported during emergence from ketamine anesthesia have been characterized as alterations in mood state and body image, dissociative or out-of-body experiences, sensations of floating, vivid dreams, and illusions. Many users report their visit to "K-land" or the "K-hole" as actually better than the "trip" produced by PCP or LSD because it usually lasts for less than an hour. These LSD-like trips coupled with the fact that ketamine, until August 1999, was not a controlled/scheduled substance have led to reports of increasing ketamine abuse. This laboratory has seen requests for ketamine analysis from DOD criminal investigative agencies grow from I in 1997 and 2 in 1998 to 14 in 1999 and 116 in 2000. Ketamine has also been involved in three military fatalities since 1998.
Whereas the metabolism and pharmacokinetics of ketamine has been reported elsewhere (7) (8) (9) (10) , there are very few data on the concentrations of parent drug and its metabolites in human urine. Additionally, there remains some question as to whether DNK is an artifact of high temperature gas chromatography procedures or a true metabolite (4, 9) . In this report, we hope to expand the database on both of these issues. This information will be required before ketamine or one of its metabolites can be added to the routine drugs of abuse screening in the DOD random urinalysis program.
Feng et al. (7) found large variations in plasma concentrations of ketamine 5 rain after bolus injections of 20 mg over a 5-rain period in humans. They concluded this implied marked interindividual differences in ketamine metabolism in humans. LSscher et al. (8) cited many similarities between ketamine pharmacodynamics/pharmacokinetics and those of the short acting barbiturates and suggested that the variability in both anaesthetic effects and metabolism of ketamine may ultimately be attributed to the biodistribution of this highly fat-soluble compound. There has also been documentation that chronic administration of ketamine results in an increase in activity of hepatic drug-metabolizing enzymes, including those responsible for metabolism of ketamine itself (9) . These self-inductive effects could not only modify the effects of the drug experienced by chronic abusers (tolerance), but may also provide additional explanation for the variability in urinary metabolite concentrations.
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In the presented study, 33 cases were positive for ketamine; in each case, DNK was detected and NK was detected in 32 cases. The presumptive DNK concentration was greater than the K or NK concentrations in 28 of the 33 cases. This suggests that DNK would be the most sensitive target analyte for a potential immunoassay that would be required for high volume screening of ketamine abuse.
Three cases (3,13,28) had parent drug present in highest concentration. One would suspect that these were cases where the urine specimen was collected closest to the time of last use. The history surrounding case 13 is unknown; however, it appears that the history of the other two cases do not support this hypothesis. As stated, individual differences in metabolism presumably account for the differences in the relative amounts of ketamine, NK and DNK in these specimens.
These individual differences are also demonstrated by comparing K/NK and K/DNK ratios (Table I ) in associated cases, that is, those cases that were collected as a result of a single investigation. For example, cases 16 and 17 were specimens collected as a result of a single investigation. The K/NK ratios were 0.272 and 0.600, respectively and the K/DNK ratios were 0.714 and 0.196, respectively. Similarly, cases 19-21 were related; K/NK ratios ranged from 0.335 to 0.766 and K/DNK ratios were from 0.159 to 0.486.
The most comprehensive controlled studies of urinary excretion were reported by Wieber et al. (10) . They found that ketamine, NK, and DNK were all detectable in the urine within 3 h following an intravenous (IV) bolus injection of 2.5 mg/kg ketamine. They used a GC-flame-ionization detection (FID) method for quantitation of parent drug and metabolites in serum and urine with a LOQ of 25 ng/mL. They reported the urinary tl/2 of ketamine was 3.37 • 0.14 h (undetectable after 22 h), t]/2 NK was 4.21 + 0.35 h (undetectable after 22 h), and tl/2 DNK was 7.21 + 1.39 h (undetectable after 60 h). In the cases reported here, ketamine and NK appear to be excreted for much longer than 22 h. This may be doserelated; we had no indication of amount ingested nor route of ingestion in any of these cases. One could predict that doses in an abuse situation would be much higher than the controlled study and would most likely be ingested orally or smoked as opposed to administered IV.
In the Wieber study, the total urinary excretion of all three metabolites amounted to about 20% of the injected dose over the first 72 h. The remaining 80% of the dose was felt to be excreted as the glucuronide conjugate. It is possible, therefore, that the detection of metabolites could be extended beyond 72-h post-ingestion with the addition of a hydrolysis step. Future work will hopefully clarify this issue.
Whereas Wieber at al. (10) reported detection and quantitation of DNK, later researchers (4,9) theorized that DNK was an analytical artifact. In 1981, Stenberg and Idvall primarily questioned the in vivo existence of DNK based on the fact that previously reported bioassays used gas-liquid chromatography and included a benzene extraction of a strongly alkalinized sample, followed by heptafluorobutyric anhydride derivatization in the presence of pyridine. They felt that the r and ~-hydroxy ketones, such as the confirmed metabolite hydroxy-norketamine, would be easily converted to the respective dehydro compounds under those harsh chemical conditions. Later, White et al. (9) agreed that dehydronorketamine was most likely an artifact but felt that it was due to the instability of the hydroxylated metabolites at high temperatures. These views were further supported by Adams et al. (11) . They theorized that these compounds would undergo thermal dehydration to form the cyclohexenone oxidation product, dehydronorketamine. The LC-MS method developed for this report addresses both of those issues. The extraction method for the LC procedure is at a relatively neutral pH, is not extracted into a reactive organic matrix such as benzene, and requires no derivatization step. Additionally, the LC was maintained at 35~ eliminating the possibility of thermal dehydration. We believe that the presumptive detection of DNK under these relatively benign conditions adds evidence to the establishment of DNK as a true metabolite of ketamine.
